3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Status
Completed
2
Recruiting
1
Sponsor Class
INDUSTRY
4
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Other hematologic neoplasm
3
Lymphoid
3
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
25
Lymphoma, Mantle-Cell
16
Lymphoma, Large B-Cell, Diffuse
11
Lymphoma, Non-Hodgkin
5
Lymphoma
5
Lymphoma, B-Cell, Marginal Zone
4
Lymphoma, Follicular
3
Leukemia, B-Cell
3
Waldenstrom Macroglobulinemia
2
Lymphoma, B-Cell
2
Leukemia
2
Cardiovascular Diseases
2
Pyloric Stenosis, Hypertrophic
1
Neuritis
1
Neoplasm, Residual
1
Lymphoproliferative Disorders
1
Hematologic Neoplasms
1
Anemia, Hemolytic, Autoimmune
1
Interventions
Cyclophosphamide
10
fludarabine
7
Rituximab
6
Bendamustine Hydrochloride
5
venetoclax
4
obinutuzumab
4
Lenalidomide
4
ofatumumab
3
ibrutinib
3
fludarabine phosphate
3
acalabrutinib
3
Vincristine
3
Immunotherapy, Adoptive
3
pirtobrutinib
2
Bortezomib
2
Alemtuzumab
2
zanubrutinib
1
thymoglobulin
1
tenofovir alafenamide
1
ricolinostat
1
pembrolizumab
1
pegaspargase
1
nelarabine
1
idelalisib
1
blinatumomab
1
Whole-Body Irradiation
1
Prednisolone
1
Pentostatin
1
Panobinostat
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, B-Cell
×
acalabrutinib
×
Clear all
NCT04883749
2025-06-08
CLL-Frail
German CLL Study Group
Phase 2
Completed
53 enrolled
NCT03787264
2024-12-30
CLL2-BAAG
German CLL Study Group
Phase 2
Completed
46 enrolled
NCT03899337
2023-01-09
STELLAR
University of Birmingham
Phase 2
Recruiting
105 enrolled